Skip to main content
Premium Trial:

Request an Annual Quote

Zymark and Bayer Collaborate on Cell-Based Transcription Assay

NEW YORK, Jan 2 – Bayer and Zymark of Hopkinton, Mass. have developed a cell-based assay kit that allows laboratories to design assays for any gene target or type of cell and run an automated assay, the companies announced Tuesday.

The package includes Bayer’s QuantiGene assays, HV kit, and ProbeDesigner software, as well as Zymark’s Staccato workstation.

The QuantiGene assay and HV kit is designed to measure the expression of cellular mRNA without the sample preparation phase. The ProbeDesigner software allows a researcher to design specific probes for mRNA targets.

According to Bayer, the Staccato workstation can complete 10,000 assays in 24 hours, and can be adapted easily for assays on different gene targets.

" Through the collaboration with Zymark, our companies are able to provide an assay solutions package employing innovative mRNA quantitation technology and the latest in high-throughput automation,” said Stephen Chamberlain, senior marketing manager for QuantiGene technologies at Bayer. “We are helping laboratories streamline their lead identification and validation processes by providing the means to obtain data of high value, eliminating the time required to develop the assay, and shortening the overall run time.”

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.